Phase 3 Lung Cancer Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with a specific type of lung cancer called lung adenocarcinoma, confirmed through a tissue or cell sample.
- People whose cancer has spread to other parts of the body (metastatic disease).
- People who are receiving the combination treatment of pembrolizumab, pemetrexed, and carboplatin as approved for use.
- People who have at least two measurable tumour spots visible on a CT or MRI scan — one that can be reliably measured over time, and one that is between 15–40 mm and located in an area suitable for a freezing treatment called cryoablation (such as the lung, kidney, adrenal gland, soft tissue, or certain bone lesions — liver and certain bone lesions cannot be treated this way).
- People aged 18 or older.
- People who are well enough to carry out basic daily activities (a health score of 2 or lower on a standard medical scale).
- Women who could become pregnant must have a negative blood pregnancy test before entering the trial.
- People who have largely recovered from any side effects of previous cancer treatment (minor side effects, or hair loss, are acceptable).
- People covered by the French social security system, in line with French research law.
- People who are willing and able to attend scheduled visits and follow the study plan.
- People who have given their written consent to participate before any study procedures begin.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose lung cancer is a squamous cell type or any type other than adenocarcinoma.
- People who have previously received systemic (whole-body) treatment for advanced lung cancer, except for treatment given after a complete surgical removal of earlier-stage cancer.
- People who have used immunosuppressive medications, including oral steroids, within 21 days before starting pembrolizumab.
- People with a known allergy or medical reason to avoid the immunotherapy drugs (PD-1/PD-L1 blockers) or chemotherapy used in this trial.
- People with a known medical reason that prevents them from safely having cryoablation (the freezing treatment).
- People whose blood clotting is abnormal in a way that makes a biopsy unsafe.
- People who have had another cancer diagnosed or treated in the last 2 years, with some exceptions for certain low-risk cancers such as early cervical, skin, or prostate cancers (confirm with trial site).
- People with an active, uncontrolled infection (bacterial, viral, or fungal) that requires medication.
- People who have taken part in another clinical trial involving an experimental drug or device within the last 28 days.
- People with a known HIV, hepatitis B, or hepatitis C infection.
- People who are pregnant or breastfeeding.
- People who are unwilling to use contraception during the trial.
- People with another illness or condition that, in the doctor's judgement, could interfere with the study or create unacceptable health risks.
- People who have previously been enrolled in this same trial.
- People who are in legal custody or under guardianship.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jean PALUSSIERE, MD, Institut Bergonié
Phone: 05.56.33.33.47
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
1-year overall survival rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.